, and RG-NewCal HA ؋ Brisbane NA-H275Y viruses. Our results demonstrate that, despite the H275Y mutation leading to a minor reduction in viral fitness, the transmission potentials of three different antigenic strains carrying this mutation were comparable in the naïve ferret model.
ffective antiviral drugs provide immediate control during influenza epidemics or pandemics. Neuraminidase (NA) inhibitors are recommended by WHO for the pharmacological management of the 2009 pandemic H1N1 viruses [A(H1N1)pdm09], which carry the S31N mutation in the M2 protein that are known to confer resistance to adamantanes (ion channel blockers for influenza A viruses) (3) . A total of 350 million treatment courses of oseltamivir were distributed to countries worldwide for pandemic preparedness between 2004 and December 2009 (56) . Emergence of resistant variants has been a concern with increased NA inhibitor usage during the H1N1 pandemic, especially if such variants may spread efficiently among humans. Structure-based-designed NA inhibitors target the enzyme site (66) to block the NA activity that hydrolyzes the ␣-ketosidic linkage between sialic acid and the adjacent oligosaccharide. Such activity is important for establishing infections (44) and for the release of viral progeny (1) . NA mutations within the enzyme site that confer resistance to NA inhibitors would also reduce NA enzyme activity and thereby compromise viral fitness (19) . As different NA mutations result in different levels of NA functional loss, NA inhibitor-resistant variants have been shown to differ in their fitness in vitro and in vivo (27, 71) . The fitness of the NA inhibitor-resistant variants can also be confounded by the genetic composition of the virus, including the hemagglutinin (HA) that binds to sialic acid-containing receptors and possesses a counteracting activity to that of NA (19, 45) .
The H275Y NA mutation (using N1 numbering) is the most commonly reported mutation arising from oseltamivir selection pressure within the N1 subtype. The mutation was first isolated from 2 out of 54 human subjects post-oseltamivir treatment experimentally infected with seasonal H1N1 influenza virus (A/Texas/36/91) (20) . The H275Y mutation has also been detected in H5N1 patients after oseltamivir treatment (10, 41) . Surveillance monitoring of influenza virus susceptibility to NA inhibitors showed limited detection rates for this mutation among the N1 subtype prior to October 2007 (14, 49, 61, 64) , but since then, a globally spreading H275Y variant has emerged (11, 31, 40, 67) , leading to the dominance of an oseltamivir-resistant variant over the sensitive H1N1 strains. Epidemiological studies could not provide evidence to link this finding to oseltamivir usage, suggesting that the transmissibility of the H275Y variant was at least comparable to that of the circulating oseltamivir-sensitive strains (11, 26, 47) . The sudden increase of the H1N1 oseltamivir-resistant viruses occurred concurrently with a major change of HA antigenicity, specifically, the change from A/New Caledonia (Brisbane; ). In addition to the change in HA antigenicity, Sandbulte et al. recently reported a major change in NA antigenicity that was associated with the emergence of the Brisbanelike virus (58) . Studies have shown that the presence of secondary mutations (4) or epistatic mutations (39) within NA may restore the NA function upon acquisition of the H275Y mutation. Specifically, the V234M and R222Q amino acid changes have been shown to increase surface NA expression while accommodating the H275Y NA mutation (4) . Furthermore, mutations occurring in the HA have been reported to promote the replication of seasonal H1N1 viruses with the H275Y NA mutation (16) . Collectively, these studies indicate that the fitness outcome of viruses carrying the H275Y mutation may be varied across antigenetic strains, and therefore the emergence of new variants merits independent investigations.
The A(H1N1)pdm09 virus, which emerged through genetic reassortment, contains gene segments derived from human, swine, and avian origins (15, 62) , with the HA from the classical Swine influenza virus (descendant of the 1918 pandemic virus) and the NA from the Eurasian swine influenza virus (which originated in an avian reservoir) (59) . While an increased usage of NA inhibitors was expected during the pandemic period, the detection rate of the H275Y NA mutation among A(H1N1)pdm09 viruses was reported as only Ͻ2% in the general population (6, 7, 46, 68) . A case-controlled study identified immunosuppression as the major risk factor associated with detection of an oseltamivirresistant H275Y variant among hospitalized patients (6) . The transmission of the A(H1N1)pdm09 variant carrying the H275Y NA mutation was found to be limited (9, 18, 42, 50) , although more recent studies have suggested the presence of community transmission of oseltamivir-resistant H275Y variants in the United States and Australia during 2010-2011 (32, 63) . The fitness of clinically derived or recombinant A(H1N1)pdm09 H275Y variants compared to their respective wild-type counterparts has been evaluated using in vitro and animal models (5, 13, 23, 37, 48, 52, 60) . The majority of these reports found that A(H1N1)pdm09 virus carrying the H275Y mutation had comparable replication efficiency and transmissibility as that of their wild-type counterparts (23, 37, 48, 60) , while some investigators detected a slightly compromised viral fitness (5, 13, 24) . Overall, there was little correlation between the epidemiological data and the laboratorybased in vitro or in vivo experimental findings, and there is a need to reevaluate the role of the H275Y NA mutation in viral fitness by using selectively different virus strains to serve as control groups.
To achieve a comprehensive understanding of the various degrees of NA functional loss that have been implicated by studies of the H275Y NA mutation, here we have adopted a systematic approach by generating three pairs of recombinant H1N1 viruses that differ in their NA genes. The first pair is A(H1N1)pdm09 A/California/04/09 (CA04) viruses with or without the H275Y NA mutation. Two other pairs of oseltamivir-sensitive (wild-type) and resistant recombinant CA04 viruses were generated for comparison, with their NA gene derived from the NewCal and Brisbane human seasonal H1N1 influenza virus strains known to possess different transmissibilities in human populations based on epidemiological data. While previous studies focused primarily on the A(H1N1)pdm09 viruses alone, we have included two previous human seasonal H1N1 viruses into the study design. This approach allowed us to directly compare the effect of the H275Y NA mutation in three different NA backgrounds. The NA enzyme properties were characterized, and the viral replication efficiencies in conventional cell lines and in differentiated human normal bronchial epithelial (NHBE) cells were evaluated. Lastly, the transmissibilities of the CA04 recombinant viruses via direct contact or respiratory droplet routes were further compared to those of the seasonal NewCal and Brisbane viruses. This study provides the first in vitro and in vivo comparison of the effect of the H275Y mutation across three antigenic strains exhibiting different epidemiological outcomes.
MATERIALS AND METHODS
Compounds. NA inhibitors oseltamivir carboxylate [GS4071; 4-Nacetyl-5-amino-3-(1-ethylpropoxy)-1-cyclohexane-1 carboxylic acid] was provided by Hoffmann-La Roche (Basel, Switzerland), and zanamivir (GG167; 4-guanidino-Neu5Ac2en) was provided by GlaxoSmithKline (Stevenage, United Kingdom). The compounds were dissolved in sterile DNase/RNase-free water, and 10 mM aliquots were stored at Ϫ20°C until used.
Viruses and cells. A/New Caledonia/20/99 (NewCal) and A/Brisbane/ 59/07 (Brisbane) seasonal H1N1 influenza viruses were kindly provided from Ian Barr (WHO Collaborating Centre for Reference and Research on Influenza, Australia); the A(H1N1)pdm09 A/California/04/09 (CA04) virus was provided by Robert G. Webster at St. Jude Children's Research Hospital. Madin-Darby canine kidney (MDCK) cells and human embryonic kidney 293T cells were obtained from the American Type Culture Collection and were maintained in minimum essential medium (MEM) with 10% fetal calf serum (FCS) and Opti-MEM (Invitrogen) supplemented with 5% FCS, respectively. MDCK-SIAT1 cells, which overexpress human ␣-2,6-sialyltransferase, were kindly provided by Mikhail N. Matrosovich (Philipps University, Marburg, Germany) and were maintained as previously described (43) . Differentiated NHBE cells derived from human donors were generated as described previously (8) . Briefly, NHBE cells (Lonza) were expanded in tissue culture flasks no more than three times before seeding onto human collagen IV-coated transwell inserts in 24-well plates to allow differentiation in an air-liquid interface for at least 28 days in an incubator (5% CO 2 , 37°C) with BEBM medium (Lonza) supplemented with retinoic acid as previously described (8) . The BEBM medium from the basolateral compartment was changed every other day. Human bronchial epithelial cells (HBEC) were isolated from patients who had undergone an operation at Queen Mary Hospital, Hong Kong; HBEC were isolated as described previously (17) and differentiated under the same conditions as NHBE cells.
Generation of recombinant viruses. The full genome of CA04 and Brisbane viruses as well as the HA and NA genes of NewCal virus were amplified by one-step reverse transcription-PCR (RT-PCR; Qiagen) and cloned into the pHW2000 plasmid as described previously (28) . The H275Y mutation was introduced into the plasmid carrying the NA gene for all three viruses by site-directed mutagenesis (Agilent Technologies). Recombinant viruses in the CA04 genetic background were generated by transfecting human embryonic kidney 293T cells (TransIT-LT1; Mirus) with eight plasmids. Cocultured MDCK and 293T cells were used to rescue the Brisbane and NewCal viruses due to low viral yields when we used 293T cells alone. The rescued viruses were then propagated in MDCK cells for two or three passages at a multiplicity of infection (MOI) of 0.001 PFU/cell to prepare stocks. The HA and NA of the recombinant viruses were verified.
Infectivity and replication kinetics. The 50% tissue culture infectious dose (TCID 50 ) was determined by incubating serial half-log dilutions of virus in MDCK cells at 37°C for 72 h. A hemagglutination assay was performed to determine the endpoint of infection, and the TCID 50 was calculated by the Reed-Muench method (57) . A plaque assay was performed by incubating serial dilutions of virus in confluent MDCK cells seeded onto 6-well plates. After 1 h of incubation at 37°C, inocula were removed and overlaid with infection medium (MEM with 0.3% bovine serum albumin) containing 0.4% agarose. Plaques were visualized after incubation at 37°C for 3 days by overnight fixation with 4% formaldehyde in phosphate-buffered saline (PBS) followed by staining with 0.2% crystal violet. Replication kinetics in MDCK or MDCK-SIAT1 cells was determined in triplicate wells at an MOI of 0.001 PFU/cell. After incubation, the cells were washed and overlaid with infection medium. Supernatants were collected at 8, 12, 24, 36, 48 , and 60 h postinfection and stored at Ϫ80°C prior to virus titration. Replication kinetics in differentiated NHBE and HBEC was determined at an MOI of 0.01 PFU/cell. To test the potential effect of mucin at the initial stage of infection, NHBE cells were divided into two groups, either with or without extensive PBS washings prior to infection. Cells were infected via the apical side with 200 l of diluted virus. After 1 h of incubation at 37°C, viral inoculum was removed; both apical and basolateral surfaces of the transwell were washed once with PBS before replenishment with fresh medium and incubation at 37°C. Virus was collected at 24, 48, 72, and 96 h postinfection by adding 200 l medium onto the apical surface followed by equilibration for 15 to 20 min at 37°C, samples were stored at Ϫ80°C for later titration.
Competitive growth of RG-CA04 and RG-CA04 NA-H275Y in differentiated NHBE and in MDCK-SIAT1 cells. RG-CA04 and its mutant counterpart RG-CA04
NA-H275Y were mixed into four different ratios to infect prewashed differentiated NHBE cells in duplicate transwells at an MOI of 0.01 PFU/cell. Total RNA was extracted from the inoculum (0 h postinfection) and viruses were collected from differentiated NHBE cells at 24, 48, and 72 h postinfection (RNeasy; Qiagen). A 475-bp PCR product was amplified (One-step RT-PCR; Qiagen) using specific primers (forward, 5=-AGAACTCAAGAGTCTGAATGTG-3=; reverse, 5=-TCCCAGTCCAT CCGTTCG-3=). The RT-PCR product was cloned into the pCR4-TOPO vector (Invitrogen). Plasmid DNA was isolated (Miniprep; Qiagen), and a total of 20 to 40 clones were sequenced using the T3 primer, covering the nucleotide encoding residue 275.
To test the inhibitory effects of oseltamivir in a coinfection environment, competitive growth was repeated in the presence or absence of oseltamivir carboxylate by using MDCK-SIAT1 cells at an MOI of 0.001 PFU/cell. Sensitivity of RG-CA04 virus to oseltamivir carboxylate was predetermined in MDCK-SIAT1 by using serial 3.16-fold dilutions of oseltamivir carboxylate (the final concentration ranged from 0 to 100 M in triplicate samples). The half-maximal effective concentration (EC 50 ) was determined by plotting virus titer as a function of compound concentration, followed by variable-slope dose-response curve fitting using GraphPad Prism software. We performed the competition assay in MDCK-SIAT1 cells under two conditions: in the absence or presence of 0.2 M oseltamivir carboxylate, which is approximately at the EC 40 , according to the dose-response curve for the RG-CA04 virus. Prior to infection, MDCK-SIAT1 cells were preincubated with medium or with medium containing 0.2 M oseltamivir carboxylate for 1 h at 37°C. After 1 h, cells were infected using RG-CA04 and RG-CA04
NA-H275Y viruses that were mixed into five different ratios at an MOI of 0.001 PFU/cell. Total RNA was extracted from the inoculum (0 h postinfection) and from viruses collected at 24 and 48 h postinfection. TOPO clonal sequencing was repeated using the same methods described above.
NA inhibition assay and NA kinetics. NA inhibition was assayed with viruses standardized to an equivalent NA enzyme activity. Viruses were first incubated with oseltamivir carboxylate or zanamivir at concentrations of 0 to 100 M at 37°C for 30 min, after which the mixtures were further incubated with the fluorogenic substrate 2=-(4-methylumbelliferryl)-␣-D-N-acetylneuraminic acid (MUNANA) at a final concentration of 167 M (22, 53) at 37°C for 30 min. The reaction was stopped by adding 150 l stop solution (0.014 M NaCl, 0.1 M glycine in 25% ethanol; pH 10.7). The half-maximal inhibitory concentration (IC 50 ) for each virus was determined by plotting fluorescence as a function of compound concentration, followed by variable-slope dose-response curve fitting using GraphPad Prism software. NA kinetics with MUNANA were determined at final concentrations of 0 to 600 M at 37°C in a total volume of 50 l with viruses diluted to approximately 5,000 PFU/ml. The fluorescence of the released 4-methylumbelliferone was measured every 68 s for 68 min by using FLUOstar Optima (BMG Labtech), with excitation and emission wavelengths of 355 and 460 nm, respectively. NA kinetics using sialosides 3=-sialyllactose (3=SL) and 6=-sialyllactose (6=SL) as the substrates (Carbosynth, United Kingdom) were determined in a coupled enzyme assay. Viruses (standardized to approximately 1.74 ϫ 10 6 PFU/ml) were incubated with 3=SL (final concentration, 0 to 4,500 M) or 6=SL (final concentration, 0 to 7,500 M) at pH 6.0 with 0.2 M phosphate buffer, excess galactose oxidase (Sigma-Aldrich), horseradish peroxidase (Invitrogen), and Amplex UltraRed reagent (Invitrogen). The reaction was conducted at 37°C, and the fluorogenic product was measured every 5 min for 4 to 6 h using FLUOstar Optima (BMG Labtech), with excitation and emission wavelengths of 530 and 590 nm, respectively. The enzyme kinetics data were fitted to the Michaelis-Menten equation by using nonlinear regression (GraphPad Prism) to determine the Michaelis constant (K m ) and maximum velocity (V max ) of substrate conversion.
Transmission experiments in ferrets. Transmissibility was tested in 4-to 6-month-old male ferrets obtained from Southland (New Zealand) or Sangosho (China). All studies were conducted in a biosafety level 3ϩ facility at the LKS Faculty of Medicine, the University of Hong Kong, in compliance with all applicable laws and with ethics approval from the Committee on the Use of Live Animals in Teaching and Research (CULATR) at the University of Hong Kong. Ferrets used in the study were confirmed to be seronegative against influenza virus A NP protein by using the ID Screen influenza virus A antibody competition enzymelinked immunosorbent assay kit (ID.vet) and had a hemagglutination inhibition (HI) titer of Յ20 against pandemic influenza H1N1 virus (A/ CA/07/2009) and influenza B virus (B/Brisbane/60/08). Virus transmission experiments used groups of two inoculated ferrets, two naïve direct contact ferrets, and two naïve respiratory droplet contact ferrets. Donors were inoculated intranasally with 10 4 PFU of recombinant virus in 0.5 ml medium under isoflurane anesthesia. All recombinant viruses used were stock viruses after two passages in MDCK cells, except for RG-CA04, which were passaged three times in MDCK cells. After 1 day, a naïve direct contact ferret was placed in the same cage with each inoculated ferret, and one naïve respiratory droplet contact ferret was placed in an adjacent compartment of the cage, separated by a single-layered perforated divider. To monitor virus shedding, nasal washes were collected from all ferrets every other day for 14 days and titrated in MDCK cells. The area under the curve (AUC) was calculated for each ferret as an approximation of the cumulative amount of virus shed in the nasal washes over time by using GraphPad Prism software. Ferret body temperatures and clinical signs were monitored daily, and weights were recorded every other day. Naïve respiratory droplet contact ferrets were handled before naïve direct contact ferrets, and inoculated ferrets were handled last; hands and equipment were disinfected before and after handling each ferret. Separate gloves and tools were used for respiratory droplet contact ferrets.
RESULTS
Generation and characterization of A(H1N1)pdm09 H1N1 recombinant viruses encoding different NA genes. Three pairs of recombinant CA04 viruses that contain NA genes from three selected strains were generated, with each pair differing by the H275Y NA mutation alone: RG-CA04, RG-CA04
NA-H275Y , RG-CA04 ϫ Brisbane NA , RG-CA04 ϫ Brisbane NA-H275Y , RG-CA04 ϫ NewCal NA , and RG-CA04 ϫ NewCal NA-H275Y . Recombinant viruses were generated via the eight-plasmid system in 293T cells as described previously (28); virus stocks were prepared in MDCK cells after two to three passages at an MOI of 0.001 PFU/cell. The susceptibilities of the recombinant viruses to zanamivir and oseltamivir carboxylate were determined in enzyme-based NA inhibition assays. We observed that the H275Y NA mutation led to an over-1,000-fold increase in oseltamivir carboxylate IC 50 s, with RG-CA04 ϫ Brisbane NA-H275Y exhibiting the greatest with respect to its wild-type counterpart. All viruses remained sensitive toward zanamivir ( Table 1 ). All recombinant viruses grew to comparable titers, suggesting that the H275Y NA mutation did not significantly affect the growth of the virus in MDCK cells (Table 1) . Furthermore, the comparable growth between RG-CA04 and RG-CA04 ϫ Brisbane NA or RG-CA04 ϫ NewCal NA suggested that the HA/NA balance was not significantly impaired when we used these particular HA/NA combinations.
The HAs and NAs of the stock recombinant viruses were sequenced to ensure their identities to the field strains; the introduced H275Y NA mutation was confirmed to be maintained in the recombinant viruses after two to three passages in MDCK cells. Heterogeneous plaques were noticed with increased passage of the recombinant viruses in MDCK cells. To explore whether these heterogeneous plaque phenotypes were related to possible mutations occurring in HA and NA gene sequences, the RG-CA04 and RG-CA04
NA-H275Y viruses were subjected to three rounds of plaque purification in triplicates. The clinically derived isolate A/California/04/2009, which was grown in MDCK for five passages, also exhibited heterogeneous plaque morphology and was included for analysis. Viral RNA was extracted from the third round of plaque expansion, and the HA and NA genes were amplified using one-step RT-PCR and analyzed by Sanger sequencing. After three rounds of plaque isolation and expansion in MDCK cells, 8 of the 18 viruses did not retain homogeneity in plaque size ( Table 2) . Assessment of the 10 homogeneous phenotypes showed amino acid changes in the HA or NA, although we did not observe any common mutation that could be associated with the observed large or small plaque morphology for the recombinant RG-CA04 or RG-CA04
NA-H275Y viruses (Table 2 ). In contrast, the G155E (H1 numbering) HA mutation was observed consistently from the large plaques isolated from the clinically derived CA04 virus in all triplicates (Table 2 ). This HA mutation has been previously reported for the A(H1N1)pdm09 virus as one of the mutations contributing to increased virulence after adaptation in mice (34) . The S183P mutation was detected in both small and large plaques for the clinically derived isolate and has also been linked with increased virulence in mice (70) . Overall, we observed heterogeneity in plaque morphology of the recombinant A(H1N1)pdm09 virus after passaging in MDCK cells; while sporadic mutations were found in HA or NA after three rounds of plaque purification in MDCK cells, the consensus sequence remained identical to the field strain. NA enzyme kinetics revealed that the H275Y NA mutation leads to differential NA functional loss in different NA backgrounds. To evaluate the effect of the H275Y framework mutation on NA enzyme activity, kinetics assays were performed using the fluorogenic substrate MUNANA or 3=SL and 6=SL with standardized viral doses based on the PFU. Viruses carrying the H275Y mutation showed lower V max and higher K m values (except RG-CA04 NA-H275Y in catalyzing 3=SL) compared to their wild-type counterparts ( Table 3 ), suggesting that the H275Y mutation generally led to decreased NA activity and a reduced affinity for substrates.
When we applied the fluorogenic MUNANA substrate for enzyme kinetics, we observed that the H275Y mutation significantly reduced the NewCal and Brisbane NA activities by 40% (P Ͻ 0.05), while only a minor reduction (10%) was observed for CA04 NA activity (Table 3 , V max and V max ratio). In addition, the H275Y mutation increased the K m for CA04, NewCal, and Brisbane NAs (Table 3) . It was noted that the K m of RG-CA04 ϫ Brisbane NA was significantly lower (14 M) than that of RG-CA04 ϫ NewCal NA (42.3 M; P Ͻ 0.05) or RG-CA04 (26.5 M). The K m for RG-CA04 ϫ Brisbane NA-H275Y (26.4 M) was more comparable to that of RG-CA04 ϫ NewCal NA or RG-CA04 viruses. This observation is consistent with a previous report by Rameix-Welti et al., who compared the enzymatic properties of seasonal H1N1 influenza viruses (54) .
A similar trend was observed when applying 3=SL or 6=SL as the substrates for enzyme kinetics; the H275Y mutation significantly reduced NA activity only for NewCal NA (3=SL) and Brisbane NA (3=SL and 6=SL) (P Ͻ 0.05). Interestingly, the RG-CA04 NA-H275Y virus did not show a decreased V max compared to RG-CA04 while catalyzing 3=SL, although an ϳ20% reduction in activity was observed for 6=SL. Using 3=SL as the substrate, we observed again that the K m values of RG-CA04 ϫ NewCal NA and RG-CA04 closely resembled that of RG-CA04 ϫ Brisbane NA-H275Y and were higher than that of RG-CA04 ϫ Brisbane NA (Table 3) . Using 6=SL as the substrate, the K m values for seasonal N1 derived from NewCal or Brisbane (2,355 and 2,108 M, respectively) were observed to be lower than that of the A(H1N1)pdm09 N1 (3,469 M), suggesting that the NAs of seasonal H1N1 viruses were more efficient in catalyzing 6=SL than that of the A(H1N1)pdm09 NA. Overall, we observed that the H275Y mutation may have led to decreased NA activity and consistently led to increased K m values for NAs derived from seasonal or A(H1N1)pdm09 H1N1 influenza viruses.
Replication kinetics in MDCK cells and the MDCK-SIAT1 cell line yielded comparable virus replication rates between wild-type and corresponding H275Y mutants. To assess if the H275Y NA mutation would compromise viral growth in vitro, multicycle replication kinetics of the recombinant viruses were analyzed in MDCK and MDCK-SIAT1 cells (stably transfected with ␣-2,6-sialyl transferase) (43) at an MOI of 0.001 PFU/cell. Our data suggest no detectable growth advantage for RG-CA04 over RG-CA04 NA-H275Y in either MDCK or MDCK-SIAT1 cells (P Ͻ 0.05) (Fig. 1) . Furthermore, comparable growth was observed between RG-CA04 ϫ NewCal NA and RG-CA04 ϫ NewCal viruses or between RG-CA04 ϫ Brisbane NA and RG-CA04 ϫ Brisbane NA-H275Y viruses in SIAT1 cells (Fig. 1) . RG-CA04 ϫ Brisbane NA showed a marginally higher titer at 12 h postinfection in MDCK-SIAT1 cells to other viruses, except for RG-CA04 ϫ Brisbane NA-H275Y . Overall, the H275Y mutation in different N1-derived NAs did not lead to compromised growth efficiencies in conventional cell lines.
Recombinant viruses carrying the H275Y mutation were compromised in establishing infection in mucin-secreting differentiated NHBE cells. We continued to examine the replication efficiency of the recombinant viruses in differentiated NHBE cells, which were previously shown to express high levels of ␣-2,6-linked sialic acids, human airway trypsin-like protease, as well as ciliated and nonciliated mucin-secreting goblet cells (8) . Mucin is known to contain high level of O-linked glycans and plays an important role in host innate defense (25, 29, 36, 65) . Collectively, these properties may provide a more physiological relevant model in assessing NA inhibitor-resistant viruses. To evaluate the infectivity of the recombinant viruses with or without the H275Y mutation in differentiated NHBE cells, the cells derived from two different donors (Lonza, Switzerland) were subjected to extensive washing with PBS (cells derived from donor 1) or no washing (donors 1 and 2) prior to infection. Using cells from the prewashed protocol, all three wild-type viruses (RG-CA04, RG-CA04 ϫ NewCal NA , and RG-CA04 ϫ Brisbane NA ) were able to establish infection in 4/4 replicates, with viral titers peaking at approximately 72 h postinfection (Fig. 2) . The recombinant viruses carrying the H275Y mutation, RG-CA04
NA-H275Y , RG-CA04 ϫ NewCal NA-H275Y , and RG-CA04 ϫ Brisbane NA-H275Y , successfully established infection in prewashed cells in 3/4, 3/4, and 2/4 replicates, respectively (Fig. 2) . Comparable viral titers was observed between the replicates successfully infected by the wild-type and the H275Y counterparts, suggesting comparable replication kinetics once the infection was established. Among the transwells that were not successfully infected, no detectable plaques were found across all time points (detection limit, 10 PFU). In differentiated NHBE cells that were left unwashed in order to maintain the mucin layer intact prior to infection, we observed that recombinant viruses carrying the NA H275Y mutation showed a reduced ability to successfully initiate infection. For wild-type viruses, we observed that RG-CA04, RG-CA04 ϫ NewCal NA , and RG-CA04 ϫ Brisbane NA could establish infection in 4/5, 5/5, and 3/5 replicates of the unwashed differentiated NHBE cells, respectively (Fig. 2) . For the viruses carrying the H275Y NA mutation, RG-CA04 (3/3 replicates), RG-CA04 ϫ Brisbane NA (2/2 replicates), and RG-CA04 ϫ Brisbane NA-H275Y (3/3 replicates). It is not known if the amounts of mucin or the compositions of the mucin secreted from differentiated NHBE and HBEC were comparable. These results highlight the existence of donor-to-donor variability when using primary cells.
TOPO cloning for sequencing of coinfected RG-CA04 and RG-CA04 H275Y viruses in vitro. To understand if the A(H1N1)pdm09 virus possessed a survival advantage over its H275Y NA counterpart, RG-CA04 and RG-CA04 NA-H275Y viruses were mixed at 100:0, 71:29, 41:59, and 0:100 ratios (verified by TOPO clonal sequencing) to coinfect the differentiated NHBE cells, which were washed extensively with PBS prior to infection. For each mixture, duplicate transwells were infected using an MOI of 0.01 PFU/cell, and viruses were collected from the apical surface every 24 h until peak titers were reached, at approximately 72 h postinfection.
At ratios of 100:0 and 0:100, we observed that both the RG-CA04 and RG-CA04
NA-H275Y genotypes were stably maintained at 24, 48, and 72 h postinfection, suggesting the genetic stability of the H275Y NA mutation. With coinfection at a ratio of 71:29 (H275:Y275), we observed that RG-CA04 became dominant (100%) at 24 h (replicate 1) or 72 h (replicate 2) postinfection. For cells infected using the ratio of 41:59 (H275:Y275), we observed that RG-CA04 became dominant at 24 h (95%; replicate 1) or 72 h (90%; replicate 2) postinfection (Fig. 3A) ; however, we noticed an increase of RG-CA04
NA-H275Y in replicate 1 at 72 h postinfection. Viruses were collected at the specified time points, and mean (Ϯ standard deviation) log 10 values are shown. The detection limit was 10 PFU/ml. *, P Ͻ 0.05.
Overall, our results suggest the genetic stability of the H275Y mutation in A(H1N1)pdm09 virus and a slightly higher survival advantage of RG-CA04 over RG-CA04 NA-H275Y virus when coinfected at different ratios in prewashed differentiated NHBE cells.
We extended the competition experiment between the RG-CA04 and RG-CA04
NA-H275Y in MDCK-SIAT1 cells and further evaluated the changes of the oseltamivir-sensitive and oseltamivirresistant populations in the absence or presence of oseltamivir carboxylate. Susceptibility of RG-CA04 was first determined using increasing concentration of oseltamivir carboxylate (0 to 100 M) in MDCK-SIAT1 cells. The EC 50 (Fig. 3B) ; however, the H275 did not completely dominate over the Y275, even with a premixed ratio ( Fig. 3B) . In summary, our results suggest that RG-CA04 possesses a minor survival advantage over RG-CA04
NA-H275Y in the absence of oseltamivir carboxylate in both NHBE and MDCK-SIAT1 cells. Coinfection with H275 and Y275 genotypes in the presence of oseltamivir carboxylate resulted in a gradual depletion of the oseltamivir-sensitive H275 genotype over time.
Transmissibility of the recombinant A(H1N1)pdm09 viruses in ferrets. The transmissibility of the recombinant CA04 viruses was evaluated in the ferret model. At an inoculation dose of 10 4 PFU, ferrets infected with RG-CA04 virus exhibited greater levels of weight loss (Fig. 4A ) and were less active and playful compared to the ferrets inoculated with RG-CA04 NA-H275Y (Fig.  4B) or RG-CA04 ϫ Brisbane NA-H275Y (Fig. 4C) viruses. One of the two ferrets inoculated with RG-CA04 virus died on day 8 postinoculation, while all ferrets survived in the RG-CA04
NA-H275Y and RG-CA04 ϫ Brisbane NA-H275Y groups. Transmission from inoculated ferrets to naïve direct contact and respiratory droplet contact ferrets was observed for all three recombinant CA04 viruses at day 4 postinoculation (day 3 postcontact) (Fig. 4) . The AUC approximating the total amount of virus shed during the course of infection was calculated for each animal; while the donor or the direct contact ferrets infected by RG-CA04
NA-H275Y consistently showed lower AUC values, the differences were not statistically significant, due to small sample sizes (Table 4) . Overall, with a small sample size, we observed that RG-CA04
NA-H275Y or RG-CA04 ϫ Brisbane NA-H275Y viruses possessed attenuated pathogenicities but retained comparable transmission efficiencies to the RG-CA04 virus.
Transmissibility of the recombinant seasonal H1N1 viruses in ferrets. The transmissibility of human seasonal H1N1 virus 
DISCUSSION
The H275Y mutation that confers resistance to oseltamivir carboxylate has been detected from human infections of different influenza N1 subtypes, including seasonal H1N1 (11, 20, 31, 40, 49, 61, 67) , highly pathogenic H5N1 (10, 41) , and more recently, in A(H1N1)pdm09 viruses (18, 21, 30, 32, 63) . Epidemiological data suggest that the fitness and the transmission potential of resistant variants carrying the H275Y NA mutation may vary between strains, with the observation of the unprecedented global spread of the Brisbane-like seasonal H1N1 virus during the 2008-2009 influenza season. While different in vitro or in vivo models (5, 13, 23, 27, 33, 35, 37, 48, 52, 60) were used to evaluate the fitness of viruses carrying the H275Y mutation, its effect on different N1 NA cannot be directly compared. The effect of this mutation in vitro has been previously addressed in a systematic manner by using different seasonal H1N1 influenza viruses (2) , while in the present study we used three antigenically representative human seasonal strains, including the pandemic 2009 virus. Our results showed that the H275Y mutation consistently led to reduced NA enzyme function and a decreased ability to establish infection in mucinsecreting primary airway epithelial cells. Under coinfection conditions in NHBE and MDCK-SIAT1 cells, we also observed a minor survival advantage of RG-CA04 over RG-CA04
NA-H275Y in the absence of oseltamivir carboxylate. Despite the detections of reduced viral competencies, both seasonal and A(H1N1)pdm09 viruses carrying the H275Y mutation were efficiently transmitted to naïve direct contact or respiratory droplet contact ferrets under the same experimental condition that a control swine influenza virus could only transmit to the naïve direct contact ferrets but not to the respiratory droplet contacts (data not shown). Our results suggest that the H275Y mutation in H1N1 influenza virus leads to a minor reduction in viral fitness, with its transmission potential being minimally affected in the ferret model.
Previous studies on NA inhibitor-resistant variants have shown that mutations within or surrounding the enzyme active site can impose different levels of NA functional loss (27, 71, 72 may not be necessarily advantageous for a virus, especially during the initiation of infection. This finding has been previously reported in a study investigating the NA enzymatic properties of seasonal H1N1 virus (54) and also identified the D344N substitution among H1N1 viruses circulating in 2007-2008 as the major determinant for increased affinity to sialic acids (55) . The uniqueness of Brisbane-like NA has been described in other studies, including the identification of secondary mutations (4) or epistatic mutations (39) that may restore the NA function upon acquisition of the H275Y NA mutation.
We observed that the K m values for NA derived from seasonal H1N1 viruses were lower than that of the A(H1N1)pdm09 virus when applying 6=SL substrate, suggesting the NA derived from seasonal viruses is more efficient in catalyzing 6=SL. The adaptation of the avian origin N2 NA in humans has been previously investigated, with the observation of increased activity in catalyzing 6=SL over time (38) . As the A(H1N1)pdm09 virus acquired its NA gene from the "Eurasian" swine lineage (15, 62) , which originally came from avian species and has been established in swine since the 1970s (12, 59) , it is not clear if adaptation of avian origin viruses in swine may also lead to increased NA activity for 6=SL.
The use of mucin-secreting differentiated NHBE cells provides a physiologically relevant model to assess viruses with impaired NA activity, which viruses show little or no compromised growth in cell lines such as MDCK or MDCK-SIAT cells. Our results suggest mucin plays a protective role in innate defense; by using cells of the same donor, we showed that extensive PBS washings prior to infection rendered the cells more permissive to infection. Furthermore, we observed that recombinant viruses carrying the H275Y NA mutation, which have reduced NA activity, were less efficient in initiating infection than their wild-type counterparts in the unwashed NHBE cells, which presumably had a more intact mucin layer. It was also noted that once the infection was established, H275Y-carrying recombinant viruses could replicate to comparable titers as their wild-type counterparts, and this recapitulates the situation observed in conventional MDCK and MDCK-SIAT1 cell lines. Although we were not able to quantify the amount of mucin or other contents being secreted by the cells, these results support previous studies that influenza virus NA is functionally important for initiating infection in human airway epithelium (44) .
We addressed the relative fitness of RG-CA04 and RG-CA04 NA-H275Y by infecting prewashed differentiated NHBE cells and MDCK-SIAT1 cells with the two viruses mixed at different ratios. We observed that the H275Y mutation may have slightly reduced the survival advantage of the virus in the absence of oseltamivir carboxylate, albeit being genetically stable over time. A previous study performing coinfection of recombinant A(H1N1)pdm09 viruses carrying H275 or Y275 NA residues in human airway epithelial cells also observed enrichment of the H275 genotype after 72 h postinfection; however, no growth advantage was observed for either virus when the coinfection was performed in MDCK cells (5) . In addition to testing the survival advantage of RG-CA04 and RG-CA04
NA-H275Y in a competitive mixtures assay, the influence of oseltamivir carboxylate was also tested in MDCK-SIAT1 cells. As expected, the TOPO clonal sequencing showed that the proportion of the oseltamivir-sensitive H275 genotype progressively declined over time. More importantly, our results demonstrated the viable coexistence of oseltamivir-sensitive and -resistant populations while under partial oseltamivir pressure (exposure to the EC 40 for sensitive virus).
The transmission results showed a robust data set, which all point toward the ability for H275Y-carrying viruses to transmit efficiently to naïve ferrets either under cohousing or respiratory droplet contact settings. It has been well established through epidemiological observations that the Brisbane-like viruses carrying the H275Y mutation are easily transmissible among humans, while only low-level transmission of the H275Y variants was reported prior to 2007-2008 (14, 64) . However, our data and a previous report (33) did not find a unique transmission potential for the Brisbane NA-H275Y virus in this animal model. In fact, we showed that RG-NewCal HA,NA and RG-NewCal HA,NA-H275Y could both transmit via direct contact and respiratory droplet routes, with RG-NewCal HA,NA-H275Y showing a slight delay in respiratory droplet transmissibility. While ferrets provide a naïve animal model for us to evaluate the transmission potential of the influenza viruses, the effect of exposure to prior circulating strains cannot be fully addressed. Oseltamivir-resistant Y275 variants circulating during the 2008-2009 season showed reduced antigenicity compared to the oseltamivir-sensitive strains (69) . More recent research has also shown that the NA of Brisbane-like viruses has undergone a major drift in antigenicity from previously circulating seasonal H1N1 viruses (58) .
In conclusion, we have shown that the H275Y NA mutation conferring oseltamivir resistance can lead to NA functional loss in A(H1N1)pdm09 and seasonal H1N1 viruses. The reduced NA activity may affect the ability of the viruses to establish infection in the human airway, in the presence of mucin. However, all viruses carrying the H275Y mutation were found to be able to transmit to naïve direct contact and respiratory droplet contact ferrets. Our results support the urgent need for the development of novel antiviral compounds or alternative treatment options for the control of influenza virus infections.
